Drug intelligence / Profile preview

JCXH-112

Development stage: Preclinical
Lead developer: Immorna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

JCXH-112 is a therapeutic mRNA vaccine developed by Jiachen Xihai (Immorna Biotherapeutics) for the treatment of chronic Hepatitis B virus (HBV) infection. The vaccine utilizes mRNA technology to encode a fusion multi-epitope HBV antigen, which is designed to stimulate the host's immune system to elicit potent antiviral T-cell and antibody responses. This approach aims to overcome immune tolerance in chronic HBV patients and facilitate viral clearance. As of early 2024, the program is in the IND-enabling/preclinical stage of development, targeting both FDA and NMPA regulatory pathways.

Other names: HBV fusion multi-epitope antigen-mRNA vaccine

Beyond the preview

Go deeper on JCXH-112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JCXH-112.

Explore the full profile